Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2 phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled receptor 88 (GPR88). Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases mediated by GPR88, including Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD).

##STR00001##

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled receptor 88 (GPR88). Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases mediated by GPR88, including Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD).

##STR00001##

The present invention provides compositions comprising compounds having formulas (I), (II) or

##STR00001## and additionally provides methods for the use thereof in the treatment of various disorders including neurological disorders, cancer, diabetes, and obesity, wherein R1-R7, X, A, and Q in (I), R1-R15 in (II) and R1-R15 in (III) are as defined herein. In certain embodiments, methods for the treatment of various disorders including pain and cancer comprise topically, locally or systemically (e.g., IV, IP or orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formulas (I), (II) or (III).

The present invention provides compositions comprising compounds having formulas (I), (II) or

##STR00001## and additionally provides methods for the use thereof in the treatment of various disorders including neurological disorders, cancer, diabetes, and obesity, wherein R1-R7, X, A, and Q in (I), R1-R15 in (II) and R1-R15 in (III) are as defined herein. In certain embodiments, methods for the treatment of various disorders including pain and cancer comprise topically, locally or systemically (e.g., IV, IP or orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formulas (I), (II) or (III).

Disclosed are a compound represented by Formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, the Formula I, and an application thereof in preparing drugs for regulating blood lipids.

##STR00001##

Disclosed are a compound represented by Formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, the Formula I, and an application thereof in preparing drugs for regulating blood lipids.

##STR00001##

Disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof, preparation method thereof, and use thereof in preventing or treating fatty liver or in preparing pharmaceuticals for weight loss.

##STR00001##

The present invention relates to a novel di-amine compound, a heat-resistant resin using the di-amine compound, and a resin composition using the heat-resistant resin, and a cured film excellent in chemical resistance and film properties even by a thermal treatment at a low temperature of 200 C. or less can be obtained. The novel di-amine compound is represented by the general formula (1). The heat-resistant resin composition of the present invention or the resin composition can be suitably used in a surface protective film and an interlayer dielectric film of a semiconductor device, a dielectric layer or a planarizing layer of an organic electroluminescent element (organic EL), or the like.

##STR00001##

(In the general formula (1), R.sup.1 and R.sup.2 each are a divalent aliphatic group, R.sup.3 and R.sup.4 each are a divalent aliphatic group, aliphatic ring group, aromatic group,
a divalent organic group bonded to an aromatic group by O, CO, SO.sub.2, CH.sub.2, C(CH.sub.3).sub.2 or C(CF.sub.3).sub.2 (wherein F is fluorine),
a divalent organic group in which two or more aromatic groups are bonded by a single bond,
or a divalent organic group in which two or more aromatic groups are bonded by O, CO, SO.sub.2, CH.sub.2, C(CH.sub.3).sub.2 or C(CF.sub.3).sub.2 (wherein F is fluorine), R.sup.5 and R.sup.6 each are an organic group having any of a hydrogen atom, a halogen atom, a hydroxyl group, a nitro group, a cyano group, an aliphatic group, an aromatic group, an acetyl group, a carboxyl group, an ester group, an amide group, an imide group, and a urea group, A is a divalent aliphatic group, aliphatic ring group, aromatic group, a divalent organic group in which two or more aromatic groups are bonded by a single bond,
or a divalent organic group in which two or more aromatic groups are bonded by O, S, CO, SO.sub.2, CH.sub.2, C(CH.sub.3).sub.2 or C(CF.sub.3).sub.2 (wherein F is fluorine),
p and q each are an integer number in the range of 0 to 3),

Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restricted FAAH inhibitor.